Amphotericin B in the management of COVID-19 associated mucormycosis
DOI:
https://doi.org/10.18203/2320-6012.ijrms20230869Keywords:
Amphotericin deoxycholate, Liposomal amphotericin B, COVID associated mucormycosisAbstract
Background: Amphotericin B is considered the drug of choice for primary treatment of mucormycosis. During second wave of COVID-19 pandemic there was severe scarcity of liposomal amphotericin B. This study aims to determine role of various formulations of amphotericin and their side effects when used for the treatment of COVID-19 associated mucormycosis.
Methods: A retrospective study was conducted between May 2021 and December 2021 at a tertiary care centre. 380 patients with post-COVID rhino-orbito-cerebral mucromycosis (ROCM) were included in the study. Liposomal amphotericin B, conventional amphotericin deoxycholate, lipid complex amphotericin B was used in the treatment. Patients were observed for side effects like fever, chills, rigors, hypokalemia, renal function derangements, thrombophlebitis and respiratory difficulties.
Results: Majority of patients received liposomal amphotericin B (331) and 31 patients received conventional amphotericin deoxycholate and 5 patients were given lipid complex amphotericin B injections. The most commonly encountered side effects were of the mild type constituting chills (98% with liposomal and 100% with amphotericin deoxycholate), and fever (94% with liposomal and 74% with amphotericin deoxycholate).
Conclusions: Our study highlights the role of various formulations of amphotericin B in the treatment of COVID-19 mucormycosis.
Metrics
References
Sipsas NV, Gamaletsou MN, Anastasopoulou A, Kontoyiannis: Therapy of mucormycosis. J Fungi. 2018;4(3):90.
Dash AK, Patro S, Patro SK, Gupta AK, Biswal RN. Amphotericin B Emulsion in rhinoorbital mucormycosis: Is it most effective? Clin Rhinol An Int J. 2016;9(1):40-2.
Cavassin FB, Bau Carneiro JL, Vilas–Boas RR, Queiroz–Telles F. Sixty years of Amphotericin B: An Overview of The Main Antifungal agent used to treat invasive fungal infections. Infect Dis Ther. 2021;10(1):115-47.
Sugar AM. Mucormycosis. Clin Infect Dis. 1992;14(1):126-9.
Parfrey NA. Improved diagnosis and prognosis of mucormycosis. Medicine. 1986;65:113-23.
Lim KK, Potts MJ, Warnock DW. Another case report of rhinocerebral mucormycosis treated with liposomal amphotericin B and surgery. Clin Infect Dis. 1994;18:653-4.
Ericsson M, Anniko M, Gustafsson H. A case of chronic progressive rhinocerebral mucormycosis treated with liposomal amphotericin B and surgery. Clin Infect Dis. 1993;16:585-6.
Donnelly J, Chen S, Kauffman C, Steinbach W, Baddeley J, Verweij P, et al. Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2019;71(6):1367-76.
Walsh TJ, Hiemenz JW, Seibel NL, Perfect JR, Horwith G, Lee L, et al, et al. Amphotericin B lipid complex for invasive fungal infections: Analysis and efficacy in 556 cases. Clin Infect Dis. 1998;26(6):1383-96.
Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A, et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis. 2000;31(5):1155-63.
Langford JD, McCartney DL, Wang RC. Frozen section –guided surgical debridement for management of rhino-orbital mucormycosis. Am J Ophthalmol. 1997;124(2):265-7.
Dash AK, Patro S, Patro SK, Gupta AK, Biswal RN. Amphotericin B Emulsion in Rhino-orbital Mucormycosis: Is It Most Effective? Clin Rhinol An Int J. 2016;9(1):40-2.
Downloads
Published
How to Cite
Issue
Section
